Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6R5H

Major aspartyl peptidase 1 from C. neoformans

Summary for 6R5H
Entry DOI10.2210/pdb6r5h/pdb
DescriptorEndopeptidase, PENTAETHYLENE GLYCOL, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (11 entities in total)
Functional Keywordsaspartyl protease, secreted, cryptococcus neoformans, hydrolase
Biological sourceCryptococcus neoformans var. grubii serotype A (strain H99 / ATCC 208821 / CBS 10515 / FGSC 9487)
Total number of polymer chains1
Total formula weight39113.55
Authors
Krystufek, R.,Sacha, P.,Brynda, J.,Konvalinka, J. (deposition date: 2019-03-25, release date: 2021-04-07, Last modification date: 2024-11-13)
Primary citationKrystufek, R.,Sacha, P.,Starkova, J.,Brynda, J.,Hradilek, M.,Tloust'ova, E.,Grzymska, J.,Rut, W.,Boucher, M.J.,Drag, M.,Majer, P.,Hajek, M.,Rezacova, P.,Madhani, H.D.,Craik, C.S.,Konvalinka, J.
Re-emerging Aspartic Protease Targets: Examining Cryptococcus neoformans Major Aspartyl Peptidase 1 as a Target for Antifungal Drug Discovery.
J.Med.Chem., 64:6706-6719, 2021
Cited by
PubMed Abstract: Cryptococcosis is an invasive infection that accounts for 15% of AIDS-related fatalities. Still, treating cryptococcosis remains a significant challenge due to the poor availability of effective antifungal therapies and emergence of drug resistance. Interestingly, protease inhibitor components of antiretroviral therapy regimens have shown some clinical benefits in these opportunistic infections. We investigated Major aspartyl peptidase 1 (May1), a secreted protease, as a possible target for the development of drugs that act against both fungal and retroviral aspartyl proteases. Here, we describe the biochemical characterization of May1, present its high-resolution X-ray structure, and provide its substrate specificity analysis. Through combinatorial screening of 11,520 compounds, we identified a potent inhibitor of May1 and HIV protease. This dual-specificity inhibitor exhibits antifungal activity in yeast culture, low cytotoxicity, and low off-target activity against host proteases and could thus serve as a lead compound for further development of May1 and HIV protease inhibitors.
PubMed: 34006103
DOI: 10.1021/acs.jmedchem.0c02177
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.75 Å)
Structure validation

237735

數據於2025-06-18公開中

PDB statisticsPDBj update infoContact PDBjnumon